Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2014 Oct 24;453(3):309-15. doi: 10.1016/j.bbrc.2014.09.053. Epub 2014 Sep 26.

Thioaptamers targeting dengue virus type-2 envelope protein domain III.

Author information

1
Center for Proteomics and Systems Biology of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
2
Center for Proteomics and Systems Biology of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Department of Nanomedicine and Biomedical Engineering, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
3
Center for Proteomics and Systems Biology of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Department of Nanomedicine and Biomedical Engineering, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. Electronic address: David.G.Gorenstein@uth.tmc.edu.

Abstract

Thioaptamers targeting the dengue-2 virus (DENV-2) envelope protein domain III (EDIII) were developed. EDIII, which contains epitopes for binding neutralizing antibodies, is the putative host-receptor binding domain and is thus an attractive target for development of vaccines, anti-viral therapeutic and diagnostic agents. Thioaptamer DENTA-1 bound to DENV-2 EDIII adjacent to a known neutralizing antibody binding site with a dissociation constant of 154nM.

KEYWORDS:

Anti-viral; Dengue virus; Diagnostic agent; Envelope protein; SELEX; Thioaptamer

PMID:
25261724
PMCID:
PMC4272640
DOI:
10.1016/j.bbrc.2014.09.053
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center